News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Thrombotargets Corporation and Magellan Bioscience Group, Inc. to Collaborate


7/25/2007 12:44:23 PM

Under the terms of this agreement, Magellan Bioscience Group, Inc. will provide to Thrombotargets its compounds and extracts from fermentation broths of marine-isolated microorganisms to be screened through the revolutionary High Throughput Screening of Pathway Activity, BIOPLATFORMSCREEN™ technology. This modified HTS platforms allows to both Thrombotargets and partners to identify novel hits for entire Pathways regulating a certain biological activity.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES